Federal agents from the U.S. Postal Inspection Service, FBI, and IRS CI converged on a North Sioux City address linked to Apex Peptides. Here is what happened, what it means for the research community, and how to evaluate alternative suppliers.
Read full article →After DOJ enforcement action took Peptide Sciences offline in March, the research-peptide market reorganized rapidly. A look at what changed and where researchers are sourcing today.
Third-party COAs, endotoxin testing, research-only positioning, transparent sourcing — we outline what separates low-risk suppliers from those operating in the gray zone.
Federal agents raided Amino Asylum's operations in March 2026 as part of the same enforcement wave that took down Peptide Sciences. A factual summary of what is known.
IQON Health — Research Peptides with Full COA Documentation
US-based. Third-party HPLC and endotoxin tested. Strict research-use-only positioning. Ships same day on in-stock items.
A structured review of preclinical research on BPC-157 — mechanisms proposed, what animal studies show, and why researchers continue studying this compound despite the regulatory uncertainty.
TB-500 (a synthetic fragment of Thymosin Beta-4) has been studied in preclinical models for tissue repair and angiogenesis. Here is what the literature shows.
The July 23–24 Pharmacy Compounding Advisory Committee meeting covered seven bulk drug substances. We break down what the committee evaluated and what their recommendations mean.
Looking for a compliant domestic peptide source?
IQON Health carries BPC-157, TB-500, and other widely studied research compounds. Every batch ships with independent COA documentation.
The July 23–24 Pharmacy Compounding Advisory Committee meeting covered seven bulk drug substances.
As enforcement actions increase, compliance differentiation between suppliers matters more than ever. Here is what to look for.
IQON Health — Built for the post-enforcement era
Compliant from day one. Research-use-only. No gray-area compounds. COAs on every product.
The Peptide Digest is an independent publication covering the science, regulation, and market developments around research peptides. We follow the regulatory and enforcement landscape closely and aim to give researchers and industry observers clear, factual information without hype or agenda.
Content is for informational purposes only. Nothing here constitutes medical advice or an endorsement of any product.